IL150549A0 - Pharmaceutical parenteral composition containing a biphosphonate - Google Patents
Pharmaceutical parenteral composition containing a biphosphonateInfo
- Publication number
- IL150549A0 IL150549A0 IL15054901A IL15054901A IL150549A0 IL 150549 A0 IL150549 A0 IL 150549A0 IL 15054901 A IL15054901 A IL 15054901A IL 15054901 A IL15054901 A IL 15054901A IL 150549 A0 IL150549 A0 IL 150549A0
- Authority
- IL
- Israel
- Prior art keywords
- biphosphonate
- composition containing
- parenteral composition
- pharmaceutical parenteral
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00101044 | 2000-01-20 | ||
PCT/EP2001/000417 WO2001052859A1 (en) | 2000-01-20 | 2001-01-16 | Pharmaceutical parenteral composition containing a biphosphonate |
Publications (1)
Publication Number | Publication Date |
---|---|
IL150549A0 true IL150549A0 (en) | 2003-02-12 |
Family
ID=8167661
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15054901A IL150549A0 (en) | 2000-01-20 | 2001-01-16 | Pharmaceutical parenteral composition containing a biphosphonate |
IL150549A IL150549A (en) | 2000-01-20 | 2002-07-02 | Injectable pharmaceutical preparation containing bisphosphonate |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL150549A IL150549A (en) | 2000-01-20 | 2002-07-02 | Injectable pharmaceutical preparation containing bisphosphonate |
Country Status (29)
Country | Link |
---|---|
US (1) | US6677320B2 (ru) |
EP (1) | EP1251857B1 (ru) |
JP (1) | JP3933933B2 (ru) |
KR (1) | KR100518391B1 (ru) |
CN (1) | CN1311835C (ru) |
AR (1) | AR027245A1 (ru) |
AT (1) | ATE318137T1 (ru) |
AU (1) | AU779677B2 (ru) |
BR (1) | BR0107755A (ru) |
CA (1) | CA2406798C (ru) |
CY (1) | CY1106482T1 (ru) |
CZ (1) | CZ301961B6 (ru) |
DE (1) | DE60117362T2 (ru) |
DK (1) | DK1251857T3 (ru) |
ES (1) | ES2258070T3 (ru) |
HR (1) | HRP20020594B1 (ru) |
HU (1) | HU229054B1 (ru) |
IL (2) | IL150549A0 (ru) |
MA (1) | MA26865A1 (ru) |
MX (1) | MXPA02007057A (ru) |
NO (1) | NO329930B1 (ru) |
NZ (1) | NZ519881A (ru) |
PL (1) | PL199784B1 (ru) |
PT (1) | PT1251857E (ru) |
RS (1) | RS50166B (ru) |
RU (1) | RU2238736C2 (ru) |
SI (1) | SI1251857T1 (ru) |
WO (1) | WO2001052859A1 (ru) |
ZA (1) | ZA200205241B (ru) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000071104A2 (en) * | 1999-05-21 | 2000-11-30 | Novartis Ag | Use of bisphosphonic acids for treating angiogenesis |
CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
ITTO20020406A1 (it) * | 2002-05-13 | 2003-11-13 | Chiesi Farma Spa | Formulazioni di bisfosfonati ad uso iniettabile. |
ATE402942T1 (de) * | 2003-01-17 | 2008-08-15 | Teva Pharma | Verfahren zur reduzierung des eisengehalts bei risedronat natrium |
US20050181043A1 (en) * | 2004-02-12 | 2005-08-18 | Indranil Nandi | Alendronate salt tablet compositions |
US20050260272A1 (en) * | 2004-05-05 | 2005-11-24 | Alkermes Controlled Therapeutics, Inc. | Method of forming microparticles that include a bisphosphonate and a polymer |
US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20060069069A1 (en) * | 2004-07-15 | 2006-03-30 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the administration of calcium chelators, bisphosponates and/or citrate compounds and their pharmaceutical uses |
US20060069068A1 (en) * | 2004-07-15 | 2006-03-30 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by pathological calcification |
US7728038B2 (en) * | 2004-08-04 | 2010-06-01 | University Of Utah Research Foundation | Methods for chelation therapy |
CN101022812A (zh) * | 2004-08-23 | 2007-08-22 | 特瓦制药工业有限公司 | 固体和晶体伊班膦酸钠及其制备方法 |
AU2005310888B2 (en) * | 2004-12-02 | 2011-01-06 | Venus Remedies Limited | Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection |
US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
RU2387661C2 (ru) | 2005-02-01 | 2010-04-27 | Ф.Хоффманн-Ля Рош Аг | Полиморфная модификация в ибандроната |
CA2594802C (en) | 2005-02-01 | 2012-11-27 | Uwe Eiermann | Ibandronate polymorph a |
US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
US8158153B2 (en) * | 2005-03-17 | 2012-04-17 | Alkermes Pharma Ireland Limited | Nanoparticulate bisphosphonate compositions |
US20070088161A1 (en) * | 2005-10-19 | 2007-04-19 | Stockel Richard F | Novel chelated bisphosphonates for use as pharmaceutical agents |
WO2007074475A2 (en) * | 2005-12-27 | 2007-07-05 | Natco Pharma Limited | Novel polymorphic forms of ibandronate |
US20070264130A1 (en) * | 2006-01-27 | 2007-11-15 | Phluid, Inc. | Infusion Pumps and Methods for Use |
US20070191315A1 (en) * | 2006-02-16 | 2007-08-16 | Bengt Bergstrom | Method for administering ibandronate |
US8974801B2 (en) * | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
US20090023683A1 (en) * | 2007-07-16 | 2009-01-22 | Chandrasekhar Kocherlakota | Complexes comprising zoledronic acid and cyclodextrins |
JP5823125B2 (ja) | 2007-10-23 | 2015-11-25 | ウェルズ ファーゴ バンク ナショナル アソシエイション | ヒドロキシアパタイト標的化多腕ポリマーならびに、このポリマーから作られるコンジュゲート |
US8986253B2 (en) * | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
CN101530415A (zh) * | 2008-03-10 | 2009-09-16 | 北京德众万全医药科技有限公司 | 一种含有双膦酸盐的药物组合物及其制备方法 |
WO2009143188A2 (en) * | 2008-05-19 | 2009-11-26 | Diperna Paul M | Disposable pump reservoir and related methods |
US20100056483A1 (en) * | 2008-09-02 | 2010-03-04 | Ohio University | Methods and compositions for the treatment and prevention of bone loss |
US8408421B2 (en) * | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
AU2009293019A1 (en) * | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care Inc. | Solute concentration measurement device and related methods |
EP2180003A1 (en) * | 2008-10-21 | 2010-04-28 | Zentiva, k.s. | Preparation of ibandronate trisodium |
US8758323B2 (en) * | 2009-07-30 | 2014-06-24 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
EP3295935B1 (en) | 2009-07-31 | 2020-07-22 | Grünenthal GmbH | Crystallization method and bioavailability |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
WO2011097269A1 (en) * | 2010-02-06 | 2011-08-11 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US10188733B2 (en) | 2010-10-22 | 2019-01-29 | President And Fellows Of Harvard College | Vaccines comprising bisphosphonate and methods of use thereof |
WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
GB201200868D0 (en) * | 2012-01-19 | 2012-02-29 | Depuy Int Ltd | Bone filler composition |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
CN103070824B (zh) * | 2013-01-24 | 2014-07-16 | 天津红日药业股份有限公司 | 一种含有伊班膦酸钠的注射液 |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
CN103385882B (zh) * | 2013-07-03 | 2016-02-24 | 江苏奥赛康药业股份有限公司 | 一种伊班膦酸钠注射用组合物 |
CN108261393B (zh) * | 2015-09-27 | 2020-10-27 | 山东则正医药技术有限公司 | 一种含有唑来膦酸的注射用药物组合物 |
CN105267145B (zh) * | 2015-11-01 | 2019-06-21 | 袁旭东 | 双膦酸盐的自乳化配方和相关剂型 |
RU2657833C2 (ru) | 2015-12-01 | 2018-06-15 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и её применение |
EA033181B1 (ru) * | 2015-12-09 | 2019-09-30 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и ее применение |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
EA030671B1 (ru) | 2016-07-20 | 2018-09-28 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Препарат для лечения костных поражений, вызванных злокачественными новообразованиями |
CN114903978A (zh) * | 2018-07-03 | 2022-08-16 | 百时美施贵宝公司 | Fgf-21配制品 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2405254C2 (de) | 1974-02-04 | 1982-05-27 | Henkel KGaA, 4000 Düsseldorf | Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper |
DE2534391C2 (de) | 1975-08-01 | 1983-01-13 | Henkel KGaA, 4000 Düsseldorf | 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren |
DE2745083C2 (de) | 1977-10-07 | 1985-05-02 | Henkel KGaA, 4000 Düsseldorf | Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung |
US4252742A (en) | 1979-07-13 | 1981-02-24 | Ciba-Geigy Corporation | Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols |
DE2943498C2 (de) | 1979-10-27 | 1983-01-27 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure |
DE3016289A1 (de) | 1980-04-28 | 1981-10-29 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren |
IT1201087B (it) | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
FR2531088B1 (fr) | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
DE3428524A1 (de) | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE3434667A1 (de) | 1984-09-21 | 1986-04-03 | Henkel KGaA, 4000 Düsseldorf | 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung |
DE3512536A1 (de) | 1985-04-06 | 1986-10-16 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
IT1187828B (it) * | 1985-05-24 | 1987-12-23 | Gentili Ist Spa | Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi |
US4761406A (en) | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
DE3540150A1 (de) | 1985-11-13 | 1987-05-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE3626058A1 (de) | 1986-08-01 | 1988-02-11 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE3640938A1 (de) | 1986-11-29 | 1988-06-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
CA1339805C (en) | 1988-01-20 | 1998-04-07 | Yasuo Isomura | (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active |
DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4958839A (en) | 1988-07-12 | 1990-09-25 | Guzik Technical Enterprises, Inc. | Disc clamp employing resilient cone for spreading balls |
US4922077A (en) | 1989-01-31 | 1990-05-01 | Raytheon Company | Method of laser marking metal packages |
CA2035179C (en) | 1990-01-31 | 2001-08-14 | Gerald S. Brenner | Pharmaceutical compositions containing insoluble salts of bisphosphonic acids |
US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
DE4244422A1 (de) | 1992-12-29 | 1994-06-30 | Boehringer Mannheim Gmbh | Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel |
DE4244423A1 (de) | 1992-12-29 | 1994-06-30 | Boehringer Mannheim Gmbh | Wasserlösliche Calciumsalze der 1-Hydroxy-3-(methylpentylamino)propan-1,1-bisphosphonsäure, ihre Herstellung und Verwendung als Arzneimittel |
US5462932A (en) | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
JP3672342B2 (ja) * | 1994-09-26 | 2005-07-20 | アステラス製薬株式会社 | ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル |
US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
US5730715A (en) * | 1996-06-14 | 1998-03-24 | Becton Dickinson And Company | Method for the iontophoretic administration of bisphosphonates |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
-
2001
- 2001-01-11 US US09/758,605 patent/US6677320B2/en not_active Expired - Lifetime
- 2001-01-16 CZ CZ20022821A patent/CZ301961B6/cs not_active IP Right Cessation
- 2001-01-16 HU HU0204114A patent/HU229054B1/hu not_active IP Right Cessation
- 2001-01-16 SI SI200130514T patent/SI1251857T1/sl unknown
- 2001-01-16 JP JP2001552906A patent/JP3933933B2/ja not_active Expired - Lifetime
- 2001-01-16 AT AT01900452T patent/ATE318137T1/de active
- 2001-01-16 EP EP01900452A patent/EP1251857B1/en not_active Expired - Lifetime
- 2001-01-16 PL PL357675A patent/PL199784B1/pl unknown
- 2001-01-16 CN CNB018039510A patent/CN1311835C/zh not_active Expired - Fee Related
- 2001-01-16 IL IL15054901A patent/IL150549A0/xx active IP Right Grant
- 2001-01-16 ES ES01900452T patent/ES2258070T3/es not_active Expired - Lifetime
- 2001-01-16 MX MXPA02007057A patent/MXPA02007057A/es active IP Right Grant
- 2001-01-16 KR KR10-2002-7009365A patent/KR100518391B1/ko not_active IP Right Cessation
- 2001-01-16 DK DK01900452T patent/DK1251857T3/da active
- 2001-01-16 RU RU2002121643A patent/RU2238736C2/ru not_active IP Right Cessation
- 2001-01-16 BR BR0107755-4A patent/BR0107755A/pt not_active Application Discontinuation
- 2001-01-16 PT PT01900452T patent/PT1251857E/pt unknown
- 2001-01-16 AU AU25165/01A patent/AU779677B2/en not_active Ceased
- 2001-01-16 NZ NZ519881A patent/NZ519881A/en not_active IP Right Cessation
- 2001-01-16 WO PCT/EP2001/000417 patent/WO2001052859A1/en active IP Right Grant
- 2001-01-16 CA CA002406798A patent/CA2406798C/en not_active Expired - Fee Related
- 2001-01-16 DE DE60117362T patent/DE60117362T2/de not_active Expired - Lifetime
- 2001-01-18 AR ARP010100224A patent/AR027245A1/es not_active Application Discontinuation
- 2001-11-16 RS YUP-548/02A patent/RS50166B/sr unknown
-
2002
- 2002-06-28 ZA ZA200205241A patent/ZA200205241B/en unknown
- 2002-07-02 IL IL150549A patent/IL150549A/en not_active IP Right Cessation
- 2002-07-16 HR HR20020594A patent/HRP20020594B1/xx not_active IP Right Cessation
- 2002-07-17 MA MA26732A patent/MA26865A1/fr unknown
- 2002-07-19 NO NO20023469A patent/NO329930B1/no not_active IP Right Cessation
-
2006
- 2006-05-19 CY CY20061100651T patent/CY1106482T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL150549A0 (en) | Pharmaceutical parenteral composition containing a biphosphonate | |
IL213240A (en) | Pharmacy composition containing poly-fluorescein conjugate | |
IL145177A0 (en) | A pharmaceutical composition containing xenon | |
IL153593A0 (en) | A pharmaceutical composition containing a soluble ctla4 mutant molecule | |
IL152659A0 (en) | Pharmaceutical composition | |
GB0001621D0 (en) | Pharmaceutical compositions | |
HK1075889A1 (en) | Pharmaceutical composition | |
AU6219601A (en) | Pharmaceutical compositions | |
HUP0204555A3 (en) | Pharmaceutical composition | |
IL139210A0 (en) | A pharmaceutical composition containing a macrolide compound | |
GB0009584D0 (en) | Pharmaceutical compositions | |
HUP0400644A3 (en) | Pharmaceutical compositions containing aspirin | |
AU8576801A (en) | Pharmaceutical compositions | |
GB0031084D0 (en) | Pharmaceutical compounds | |
IL154238A0 (en) | Pharmaceutical composition | |
GB0008485D0 (en) | Pharmaceutical compositions | |
GB0009613D0 (en) | Pharmaceutical compositions | |
GB0019272D0 (en) | Pharmaceutical compounds | |
GB0024318D0 (en) | Pharmaceutical compounds | |
GB0005382D0 (en) | Pharmaceutical composition | |
GB0005366D0 (en) | Pharmaceutical compounds | |
GB0002691D0 (en) | Pharmaceutical composition | |
GB0101094D0 (en) | Pharmaceutical composition | |
SI1343530T1 (sl) | Peroralni farmacevtski sestavek, ki vsebuje blok kopolimer | |
GB0022520D0 (en) | Pharmaceutical compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |